Search - tctmd.com

Displaying 201 - 220 of 334

Sort: Relevancy | Date

Presentation TCT 2017

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Presenter: Michael S. Lee, Dirk Sibbing, John A. Bittl

October 30, 2017

Presentation TCT 2017

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Presenter: Michael S. Lee, Dirk Sibbing, David Erlinge

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

Presentation TCT 2017

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Uwe Zeymer

October 30, 2017

Presentation TCT 2017

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Eric R. Bates

October 30, 2017

$Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!$

Presentation TCT 2017

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, A. Michael Lincoff

October 30, 2017

Presentation TCT 2017

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Presenter: Michael S. Lee, Dirk Sibbing, Francesco Franchi

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2017

DAPT Duration: Individualized vs Generalized Approach

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Marco Valgimigli

October 29, 2017

Presentation TCT 2017

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Presenter: Takeshi Kimura, Shigeru Saito, Takafumi Ueno

October 29, 2017

Presentation

Lesion Complexity and Outcomes of Extended DAPT After PCI

October 23, 2017

Presentation SIF 2017

Debate: With Modern Generation DES, 3 – 6 months of DAPT Is All You Need

Presenter: William B. Bachinsky

March 10, 2017

Presentation SIF 2017

PCI Pharmacology in 2017: Understanding the Essentials

Presenter: MIchael A. Kutcher

March 09, 2017

Presentation CRT 2017

Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

Presenter: Chadi Alraies

February 22, 2017

Presentation JIM 2017

BRS - A “Stillborn” Device!

Presenter: Davide Capodanno

February 08, 2017

Presentation Cardiovascular Interventions 2016

DAPT after Stenting: How Short When Needed and How Long When Tolerated?

Presenter: Dean J. Kereiakes

November 10, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

2016 DAPT Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla

November 01, 2016

Advertisement

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Why I Use Cangrelor for Primary PCI in STEMI!

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

DAPT Duration: Individualized vs Generalized Approach

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Lesion Complexity and Outcomes of Extended DAPT After PCI

Debate: With Modern Generation DES, 3 – 6 months of DAPT Is All You Need

PCI Pharmacology in 2017: Understanding the Essentials

Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

BRS - A “Stillborn” Device!

DAPT after Stenting: How Short When Needed and How Long When Tolerated?

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

FDA Perspectives on Short DAPT IDE Trials

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

2016 DAPT Update: Evidence and Guidelines

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content